TechForce Robotics, Inc., the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics, marking the company’s first operational entry into pharmaceutical and laboratory automation. The deployment fulfills Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows.
A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications. This move from hospitality to pharma highlights the growing trend of robotics platforms adapting to new sectors.
Laboratory and pharmaceutical operations increasingly face the same challenge that has accelerated automation across industries from manufacturing to hospitality: how to improve efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.
TechForce Robotics is positioning itself to address that opportunity by extending its Robotics-as-a-Service (RaaS) platform into laboratory environments. The LIM-E robot is designed to handle material transport, sample delivery, and other repetitive tasks, potentially reducing bottlenecks and allowing skilled staff to concentrate on core research and development activities.
The implications of this announcement extend beyond a single deployment. By entering the pharmaceutical sector, TechForce is tapping into a market that demands high precision and regulatory compliance. The alliance with JJ Enterprise strengthens its capabilities in machine vision and precision engineering, which are critical for tasks such as handling sensitive materials or operating in sterile conditions. If successful, this could pave the way for broader adoption of autonomous systems in drug manufacturing and laboratory testing, ultimately accelerating the pace of discovery and production.
For investors, the news signals that TechForce is diversifying its revenue streams and targeting industries with higher barriers to entry. The company’s ability to secure a partnership with Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, suggests confidence in its technology. Further updates are expected as the joint development agreement progresses toward GMP-compliant applications.
TechForce Robotics is a subsidiary of Nightfood Holdings, Inc., which trades on the OTCQB under the symbol NGTF. More information about the company can be found in its newsroom at https://ibn.fm/NGTF. This article is based on a press release distributed by TechMediaWire, a platform focused on technology companies. For more details, visit https://www.TechMediaWire.com.
